ALSO NOTED: Senator calls for halt in DTC ads; Now, Merck faces Fosamax, Vytorin suits;

> New York Sen. Charles Schumer called for an end to direct-to-consumer drug advertising, saying that Merck and Schering-Plough misled patients about their newly controversial cholesterol drug Vytorin. Report

> One down, another pops up: With Merck poised to wrap up its Vioxx litigation, it's facing new challenges to top-selling products, including osteoporosis blockbuster Fosamax and cholesterol fighter Vytorin. Report

> Takeda Pharmaceuticals and generics maker Teva Pharmaceutical Industries await a Delaware judge's decision on their patent dispute over the proton pump inhibitor Prevacid. Report

> Teva Pharmaceutical got tentative FDA approval for its version of the prostate drug Flomax, made by Boehringer Ingelheim. Report

> Japan's Takeda Pharmaceuticals reported record operating profits for the first nine months of its fiscal year, with earnings of $3.8 billion on sales of $10 billion. Report

> Abbott Laboratories is investing up to $40 million in Isis Pharmaceuticals' mass spectrometer subsidiary Isis Biosciences. Report

> South Korean researchers have successfully tested a new approach to delivering vaccines, applying it under the tongue rather than through a needle. Report

> A patient's thoughts and feelings play a big role in determining just how effective their annual flu shot can be, says a new study. Report

AND FINALLY... Suspect that your blood pressure rises when your team is 4th-and-Goal with 15 seconds left? German researchers actually found that heart attacks more than doubled on days the national soccer team played. Report

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.